Active Ingredient(s): Cemiplimab-rwlc
FDA Approved: * September 28, 2018
Category: Cancer

Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer.[5][6] Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.[4][7] The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.[5][4] In September 2018, it was appr... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Libtayo 50 mg/ml Intravenous Injection
NDC: 61755-008
Regeneron Pharmaceuticals, Inc.

Popular Topics

Libtayo Infusion for Squamous Cell Metastesis

Has anyone had experience or positive results with this drug? My Mom has been treated every three weeks for the past 4 m...